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Abstract
Background: Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans
currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we
aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical
setting.
Methods: The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period
of 12 months. There were two principal objectives: 1) documentation of the achievement of target BP values set
according to recent national and international guidelines, and 2) description of the safety profile of AZL-M.
Results: A total of 3 849 patients with essential arterial hypertension were recruited from primary care offices in
Germany. Patients who initiated monotherapy at baseline comprising either AZL-M or an ACE-inhibitor were
included at a ratio of seven to three. Results demonstrated that a blood pressure target of <140/90 mmHg was
achieved by a significantly greater proportion of patients in the AZL-M group (61.1 %) compared with the ACE-
inhibitor group (56.4 %; p < 0.05; OR, 1.21; 95 % CI, 1.03–1.42), with this finding maintained after adjusting for
differences in baseline characteristics. AZL-M appeared to have an equivalent safety profile to the ACE-inhibitors,
with a similar incidence of adverse events in the two patient groups (p = 0.73).
Conclusions: These data add to the results of previous randomized controlled clinical trials suggesting that,
compared with other agents that target the renin–angiotensin system, AZL-M provides statistically significant albeit
small improvements in blood pressure control.
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Background
Despite the availability of many safe and effective antihy-
pertensive drugs, target blood pressure (BP) is only ob-
tained in approximately 20 % of hypertensive patients in
Germany [1]. It has been suggested that achieving a re-
duction in mean systolic BP (SBP) on the order of
2 mmHg can result in a 10 % reduction in the incidence
of fatal stroke and a 7 % decrease in death due to ischae-
mic heart disease or other vascular causes [2]. This indi-
cates the importance of developing more effective drugs
for controlling hypertension.
Angiotensin converting enzyme (ACE) inhibitors are
known to be effective in lowering BP, working by
inhibiting the enzyme responsible for converting
angiotensin I to angiotensin II in the renin–angioten-
sin system (RAS). However, they have also been asso-
ciated with side effects such as a persistent cough
and, less commonly, angioedema [3, 4]. Angiotensin
receptor blockers (ARBs) are a more recently
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introduced class of antihypertensive drugs that also
target the RAS, binding to the angiotensin receptor1
(AT1 receptor) for angiotensin II [5]. ARBs have
demonstrated similar or improved efficacy for redu-
cing BP but appear to be more tolerable, with fewer
side effects such as coughing reported [5], although
no significant differences in the occurrence of drug-
related adverse events (AEs) have been noted [6–8].
There are a number of different ARBs used to treat
hypertension, all working via the same mechanism
but displaying different efficacies [9]. Azilsartan
medoxomil (AZL-M) is the most recently approved
ARB [10], and has demonstrated the capacity to re-
duce BP to a greater extent than olmesartan, which is
considered to be the most potent of the sartans used
clinically [11, 12].
A recent phase III trial compared the efficacy of AZL-
M with the ACE-inhibitor Ramipril [13]. This compari-
son is particularly valuable as ramipril is considered to
be a benchmark antihypertensive drug that has been
shown to be highly effective in lowering BP [14, 15]. In a
randomized clinical trial AZL-M was found to be more
effective in lowering BP in comparison to ramipril; fur-
thermore, patients in the ARB group experienced fewer
AEs leading to discontinuation of treatment [13].
Based on these data, an improvement in BP control
might be expected from using AZL-M in clinical prac-
tice. The EARLY “Treatment with Azilsartan Compared
to ACE-Inhibitors in Anti-Hypertensive Therapy” registry
was designed to document BP control and its impact on
cardiovascular and renal events during a 12 month
follow-up period in patients administered either AZL-M
or an ACE-inhibitor at baseline [16].
Methods
The EARLY registry is a prospective, observational, na-
tional, multicentre registry with a follow-up period of
12 months. Follow-up visits after 6 and 12 months were
conducted by the sites. Details of the aims and design of
the study protocol have been published previously [16,
17]. In short, patients with arterial hypertension having
either no anti-hypertensive treatment prior to inclusion
or a prior non-RAS based antihypertensive monotherapy
and starting treatment on either AZL-M or any ACE in-
hibitor monotherapy in a ratio of 7 (AZL-M) to 3 (ACE-
inhibitor) were documented. Treatment decisions were
at the physician’s discretion, and groups were not
randomized.
The protocol was approved by the independent inter-
national ethics committee in Freiburg, and the ethics com-
mittee of the State Medical Council of Rheinland-Pfalz,
Germany. All patients enrolled in the registry provided
written informed consent.
Objectives
Establishment of the registry had two primary objectives:
1) documentation of the achievement of target BP values
set according to recent national and international guide-
lines [18], and 2) description of the safety profile of
AZL-M. Further secondary objectives are listed in the
protocol published previously [16] and include the 1) ab-
solute and relative BP reduction with antihypertensive
treatment over the duration of one year 2) documenta-
tion of the adherence to guidelines for the diagnosis and
treatment of hypertension in ambulatory care 3) persist-
ence understood as the mean duration of monotherapy
and/or AZL-M based combination therapy during
follow-up 4) documentation of adverse events 5) pro-
spective documentation of cardiovascular and renal
events.
Selection of sites and patients
The registry was established in primary care offices in
Germany. Centres were selected from a database main-
tained at the Institut für Herzinfarktforschung, Ludwigs-
hafen. The centres were chosen with the aim of obtaining
data that is representative of current hypertension treat-
ment in Germany.
Patients over 18 years of age with essential arterial
hypertension were included on a consecutive basis [18],
given that they had provided written informed consent
and fulfilled the following two criteria: 1) they had either
no antihypertensive treatment prior to inclusion or were
on a non-RAS based antihypertensive monotherapy, and
2) monotherapy consisting of AZL-M or an ACE-
inhibitor was initiated at baseline. Patients were
excluded from participation if they 1) received antihy-
pertensive drugs for an indication other than hyperten-
sion (e.g. beta blockers or diuretics for heart failure); 2)
had a history of alcohol, drug abuse, or illegal drug ad-
diction; 3) had a life expectancy of less than one year; 4)
were pregnant or breast feeding; or 5) were participating
in other trials or registries. Moreover, patients with con-
traindications as to the summary of product characteris-
tics of any of the drugs being prescribed were excluded.
Statistics
Reasons for choosing a 7 (AZL-M) to 3 (ACE-inhibitor)
ratio and justification for the sample size have been pub-
lished previously [16]. Continuous variables were ana-
lysed using descriptive statistics (absolute numbers,
means plus standard deviations (SD), or medians with
25th and 75th percentiles) as appropriate. Categorical
data were described by the number (n) and percentage
(%) of subjects in each category. Comparisons between
treatment groups were performed using Pearson’s chi-
squared test for categorical variables, or the Mann–
Whitney-Wilcoxon test for continuous measurements.
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To assess differences in BP between groups that dif-
fered at baseline, two multivariate models were used
(Table 2). Model 1 provided adjustments for SBP/dia-
stolic BP (DBP) at baseline; while model 2 additionally
took into account whether the hypertension was newly
diagnosed or established, age, gender, and diabetes. P-
values ≤ 0.05 were considered significant. All given p-
values are the results of two-sided tests. Statistical
analysis was performed using the SAS 9.3 software (SAS
Institute, Inc., Cary, NC, USA).
Results
Patient characteristics at baseline
The EARLY registry enrolled a total of 3 849 patients
(Fig. 1) in 509 sites. Of these, 2 809 (73.0 %) were treated
with AZL-M (mean dose 41.4 ± 21.3 mg), with 1 040 pa-
tients (27.0 %) receiving an ACE-inhibitor (mean dose
7.6 ± 11.2 mg), mainly ramipril (889 patients, 85.5 %),
reflecting the planned enrolment ratio of 7:3. Baseline
characteristics of the patients are given in Table 1. The
mean age of the overall population was 59.4 years with
slightly older patients in the AZL-M than in the ACE-
inhibitor group; there were also marginally more females
(47.9 % vs. 43.8 %). Mean body weight did not vary sig-
nificantly between treatment groups. The proportion of
total patients with a new diagnosis was 36.9 %, with the
remainder having established hypertension. There were
fewer newly diagnosed patients in the AZL-M group
(34.2 % vs. 43.9 %), and those with established hyperten-
sion had a longer mean time since diagnosis in compari-
son to the ACE-inhibitor group (67.2 ± 65.3 months vs.
57.7 ± 60.9 months; p < 0.001). Baseline office BP mea-
surements revealed that only 6.1 % of all patients had
SBP/DBP below 140/90 mmHg. The most frequent co-
morbidities of the patients are also given in Table 1,
where it can be seen that diabetes and coronary artery
disease (CAD) were the most prevalent. While the
prevalence of CAD was slightly higher in the ACE-
inhibitor group, those of the other comorbidities were
similar.
The 12 month follow-up period was completed by a
total of 3 082 (80.1 %) patients, including 2 237 in the
AZL-M group and 845 in the ACE-inhibitor group
(Fig. 1). In the group that did not complete the follow-
up, slightly fewer patients were female, had COPD, and
the average body weight was higher. There were no
other differences in baseline characteristics between the
patients that did and did not complete the follow-up.
Achievement of BP targets based on recent national and
international guidelines
Blood pressure values achieved at 12 months were 134.1
± 12.9 mmHg / 80.8 ± 8.0 mmHg for AZL-M and 134.9 ±
13.1 mmHg / 81.4 ± 8.7 mmHg for the ACE-inhibitor
group (p = 0.11 and p = 0.07, respectively; Additional file
1: Table S1). Using raw unadjusted data for patients who
completed the 12 month follow-up, mean reductions in
SBP and DBP in the AZL-M group (25.9 and 13.0 mmHg,
respectively) were greater than those recorded for the
ACE-inhibitor group (22.6 and 11.4 mmHg, respectively;
p < 0.0001 and < 0.001, respectively). Accordingly, the pro-
portion of patients who attained the target BP level of
<140/90 mmHg was greater in the AZL-M group (61.1 %)
compared with the ACE-inhibitor group (56.4 %; p < 0.05;
OR, 1.21; 95 % CI, 1.03–1.42; Table 2) overall and in sub-
groups of patients (Fig. 2). Following adjustment for base-
line SBP/DBP (model 1), and for baseline SBP/DBP, newly
diagnosed or established hypertension, age, gender, and
the presence of diabetes (model 2), compared with ACE-
inhibitor treatment, AZL-M treatment was still associated
with statistically significant reductions in SBP (p < 0.05
and 0.01 for the two respective models) and DBP (p < 0.05
for both models). Furthermore, there was a greater pro-
portion of patients who achieved a BP of <140/90 mmHg
(p < 0.01 for both models). The respective analyses for the
6 months follow-up are displayed in Additional file 1:
Fig. 1 Patient flow chart
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Table S1 and Additional file 2: Table S2, which show no
major differences compared to the 12 months analysis.
The subgroups of patients with newly diagnosed
hypertension, aged 50–69 years, and without diabetes
were found to be statistically more likely to achieve tar-
get BP when treated with AZL-M rather than an ACE-
inhibitor; and the results were significant (Fig. 2). In
contrast, gender, body mass index (BMI), and the pres-
ence of vascular disease did not significantly affect the
outcome.
Safety profile
In terms of the safety of AZL-M, there was no difference
in the proportion of patients experiencing an AE in
comparison to those being treated with an ACE-
inhibitor (p = 0.73; Table 3); however, a higher percent-
age of the AZL-M group died (10/2 237; 0.4 % vs. 1/845;
0.1 %). Causes of death were myocardial infarction (2×),
post-procedural sepsis (1×), prostate cancer (1×), pan-
creatic cancer (1×), pneumonia (1×), a road traffic acci-
dent (1×), and unknown (3×) in the AZL-M group and
unknown (1×) in the ramipril group. For one patient in
the AZL-M group that died of an unknown cause there
was uncertainty about the causal relationship between
AZL-M treatment and death. On analysis of various pa-
tient subgroups, no differences in the incidence of AEs
were apparent between the AZL-M and ACE-inhibitor
groups (Fig. 3). Furthermore, there were no significant
differences in laboratory values between the groups, in-
cluding HbAc1, fasting glucose, creatinine, potassium,
and estimated glomerular filtration rate (eGFR).
Treatment persistence
There was no evident difference between the likelihood
of patients taking AZL-M or an ACE-inhibitor in terms
of a requirement for treatment adjustment during the
12 month follow-up period (OR, 0.91; 95 % CI, 0.75–
1.12; Fig. 4). However, the patients with established
hypertension were seen to be more likely to need a
change in treatment if they were being treated with an
ACE-inhibitor (OR, 0.61; 95 % CI, 0.41–0.92).
Discussion
In the present study, the efficacy, safety, and tolerability
of antihypertensive monotherapy using either AZL-M or
an ACE-inhibitor was evaluated in real life clinical













(n = 2 809)
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Age, years 59.4 ± 13,0 58.8 ± 13.4 59.6 ± 12.9 0.29 60.1 ± 12.6 57.7 ± 13.9 <0.0001
Female, % 46.8 41.5 48.1 <0.001 47.9 43.8 <0.05
Body weight, kg 83.3 ± 15.6 84.5 ± 15.8 83.0 ± 15.6 <0.05 83.4 ± 15.8 83.1 ± 15.2 0.94
Hypertension
Newly diagnosed, % 36.9 34.7 37.4 0.16 34.2 43.9 <0.0001
Established, months 65.0 ± 64.4 65.3 ± 70.8 64.9 ± 62.7 0.49 67.2 ± 65.3 57.7 ± 60.9 <0.001
Office SBP, mmHg 159.3 ± 17.1 159.6 ± 17.9 159.3 ± 16.9 0.67 160.0 ± 17.4 157.6 ± 16.1 <0.0001
Office DBP, mmHg 93.5 ± 10.5 93.3 ± 10.8 93.5 ± 10.4 0.60 93.8 ± 10.6 92.7 ± 10.2 <0.01
BP < 140/90 mmHg, % 6.1 6.8 5.9 0.34 6.2 5.7 0.60
AZL-M treatment, % 73.0 74.6 72.6 0.27 100.0 0.0
ACE-inhibitor treatment, % 27.0 25.4 27.4 0.27 0.0 100.0
Comorbidity
Diabetes, % 19.3 17.5 19.8 0.15 19.4 19.3 0.96
Heart failure, % 5.7 5.4 5.8 0.73 5.7 5.6 0.88
CAD, % 9.6 8.9 9.8 0.44 8.9 11.5 <0.05
Prior stroke/TIA, % 2.8 3.7 2.5 0.09 2.8 2.5 0.59
PAD, % 3.0 2.5 3.2 0.31 3.0 3.2 0.73
COPD, % 7.4 3.6 8.2 <0.0001 7.2 7.7 0.58
Renal function
Known renal disease, % 3.3 2.7 3.4 0.34 3.2 3.5 0.70
Microalbuminuria, % 6.5 5.7 6.7 0.53 6.6 6.0 0.65
Legend: AZL-M azilsartan medoxomil, ACE angiotensin-converting enzyme, SBP systolic blood pressure, DPB diastolic blood pressure, CAD coronary artery disease,
TIA transient ischaemic attack, PAD peripheral artery disease. Values are indicated in percent (%), median (interquartile range), or mean ± standard deviation
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practice. The key finding was that after 12 months of
treatment, both reductions in SBP and DBP, and the per-
centage of patients who attained target BP levels, were
significantly greater with AZL-M treatment compared to
that with an ACE-inhibitor.
Efficacy outcomes in perspective
On analysis of the raw data, it was seen that the mean
reductions in SBP and DBP were greater in the AZL-M
group (Δ25.9 mmHg) relative to the ACE-inhibitor
group (Δ22.6 mmHg), with an additional 4.7 % of pa-
tients reaching the target level of BP control. Similar re-
sults were obtained after adjusting for baseline SBP/DBP
(model 1), and SBP/DBP, newly diagnosed or established
hypertension, age, gender, and diabetes (model 2). This
is in principal agreement with the data reported by
Bönner et al. and who demonstrated improved BP re-
duction for patients who were allocated AZL-M com-
pared to ramipril in a randomised trial [13]. In the
Bönner trial, the primary efficacy endpoint was the
change in clinic trough, seated systolic BP from baseline
with ambulatory BP additionally provided. AZL-M 40
and 80 mg reduced both clinic systolic BP and mean
ambulatory systolic BP significantly more than ramipril
at a dose of 10 mg (clinic SBP −20.6 ± 0.9 with 40 mg
and −21.2 ± 0.9 with 80 mg AZL-M vs.-12.2 ± 0.9 with
ramipril; p < 0.001 for both doses). Compared to these
numbers differences in the present trial were low, with
1.3 mmHg systolic (p < 0.01) and 0.7 mmHg diastolic (p
< 0.05) after adjustment (model 2). The pronounced BP
lowering effect in the Bönner RCT compared to the ob-
servational study may be the result of the selection cri-
teria that were applied in the RCT, resulting in many
patients treated in clinical practice, being excluded from
the randomized trial, for which it has been shown to
have a lesser effect [19]. The results are nonetheless im-
portant since a number of analyses have shown that
(even small) changes in blood pressure will result in a
linear reduction in morbidity and mortality [20].
Furthermore, Bönner [13] found that the difference
in blood pressure lowering remained for each of the
subgroups analysed, which included age, gender, BMI,
Table 2 Blood pressure reductions-comparison of treatment groups in patients with a 12 months follow-up
differences at 12 months vs. baseline
AZL-M
(n = 2 237)
Δ value (95 % CI)
ACE-inhibitor
(n = 845)
Δ value (95 % CI)
p-value for the comparison
of differences vs. baseline
Raw (unadjusted)
Δ SBP, mmHg 25.9 (25.1–26.7) 22.6 (21.3–23.8) <0.0001
Δ DBP, mmHg 13.0 (12.5–13.5) 11.4 (10.6–12.2) <0.001
Δ Mean BP, mmHg 17.3 (16.7–17.8) 15.1 (14.3–15.9) <0.0001
Δ Pulse pressure, mmHg 12.9 (12.2–13.6) 11.1 (10.1–12.2) <0.05
Δ Heart rate, bpm 3.0 (2.6–3.5) 2.9 (2.2–3.7) 0.64
BP < 140/90 mmHg, % 61.1 (59.0–63.1) 56.4 (53.0–59.8) <0.05
Model 1 (adjusted)
Δ SBP, mmHg 25.3 (24.7–25.8) 24.1 (23.3–25.0) <0.05
Δ DBP, mmHg 12.7 (12.4–13.1) 12.0 (11.5–12.5) <0.05
Δ Mean BP, mmHg 17.0 (16.6–17.2) 16.0 (15.5–16.6) <0.05
Δ Pulse pressure, mmHg 12.5 (12.1–13.0) 12.1 (11.4–12.9) 0.39
Δ Heart rate, bpm 3.1 (2.7–3.4) 2.9 (2.4–3.4) 0.57
BP < 140/90 mmHg, % 61.4 (59.4–63.4) 55.9 (52.5–59.2) <0.01
Model 2 (adjusted)
Δ SBP, mmHg 25.3 (24.8–25.8) 24.0 (23.1–24.8) <0.01
Δ DBP, mmHg 12.7 (12.4–13.1) 12.0 (11.5–12.5) <0.05
Δ Mean BP, mmHg 17.0 (16.6–17.3) 16.0 (15.4–16.5) <0.01
Δ Pulse pressure, mmHg 12.6 (12.1–13.0) 12.0 (11.2–12.7) 0.15
Δ Heart rate, bpm 3.1 (2.7–3.4) 2.8 (2.3–3.4) 0.50
BP < 140/90 mmHg, % 61.7 (59.6–63.7) 55.5 (52.1–58.9) <0.01
Legend: AZL-M azilsartan medoxomil, ACE angiotensin-converting enzyme, SBP systolic blood pressure, DBP diastolic blood pressure. To illustrate the adjusted
changes in BP, 3 pretreatment BP values were chosen representing the three borders between four quartiles; model 1: adjusted for SBP/DBP at baseline; model 2:
adjusted for SBP/DBP at baseline (model 1), newly diagnosed or established hypertension, age, gender, and diabetes
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clinic SBP, and eGFR. In the present registry, no dif-
ference in the rate of target BP achievement was
found in the gender and BMI subgroups; however, pa-
tients with newly diagnosed hypertension, those aged
50–69 years, and those without diabetes were more
likely to reach the target value if treated with AZL-M
rather than an ACE-inhibitor.
The efficacy of AZL-M versus ACE-inhibitors for
reducing BP may be explained by the different bio-
chemical characteristics and mechanisms of action of
the two drug classes. ACE-inhibitors work via com-
petitive inhibition of the enzyme that is responsible
for the conversion of angiotensin I to angiotensin II.
However, angiotensin II can also be produced via
other mechanisms; therefore, such a drug cannot
completely inhibit its formation [4, 21]. ARBs, on the
other hand, work as antagonists for the AT1 angio-
tensin II receptor, providing a more direct and
complete inhibition of the BP raising effects of the
RAS. Indeed, the results of the ONTARGET trial
demonstrated a greater reduction in BP for patients
treated with the ARB telmisartan in comparison to
Ramipril [22]. Another study showed the equivalent
efficacy of valsartan and lisinopril [23]. As AZL-M
has demonstrated higher efficacy for BP lowering in
comparison to other sartans, it is unsurprising that it
has performed better in the patients included in the
EARLY registry [4, 9, 11, 24].
Safety outcomes in perspective
In the present registry, no significant difference in the
incidence of AEs was observed between the AZL-M and
ACE-inhibitor groups, indicating an equivalent level of
safety. Furthermore, there were no apparent differences
in laboratory values between the two groups. On analysis
of the subgroups, again no disparity was found in the
rate of AEs with the two treatment populations. This is
in agreement with a number of other studies comparing
the safety of ARBs with that of ACE-inhibitors. Roy et
al. evaluated the incidences of death, stroke, CAD, and
chronic kidney disease in a population of hypertensive
patients being treated with one of either class of drug,
and found no significant differences between the two
groups [8]. Li et al. and Reboldi et al. reviewed the avail-
able literature regarding comparisons between ACE-
inhibitors and ARBs and both concluded that there were
no significant differences between the two drug categor-
ies in terms of total mortality risk, cardiovascular risk,
and cardiovascular mortality [6, 25]. Hasvold et al. found
a similar risk of cardiovascular disease in patients being
treated with the ACE-inhibitor enalapril and the ARB
candesartan [7], while Bönner et al. compared ramipril
with AZL-M and also found no significant variations in
the occurrence of AEs between the two groups, although
they reported a slightly higher occurrence of cough and
lower incidences of back pain and dizziness in the rami-
pril patients [13]. An observational study reported by
Fig. 2 AZL-M vs. ACE-inhibitors in patients with a 12 month follow-up–target BP achievement (<140/90 mmHg). Legend: HT, hypertension; BMI,
body mass index; target BP achievement is defined as an SBP of <140 mmHg and a DBP of <90 mmHg
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Table 3 Safety of AZL-M and ACE-inhibitors during 12 month follow-up
AZL-M ACE-inhibitor p-value
(n = 2 237) (n = 845)
mean ± SD or % mean ± SD or %
Patients without an AE, % 92.9 93.3 0.73
Patients with an AE, % 7.1 6.7 0.73
Laboratory values Baseline AZL-M Δ at 12 months FU Baseline ACEi Δ at 12 months FU p-value Δ AZL-M vs. Δ ACEi
HbA1c, % 5.9 ± 1.2 0.01 ± 0.97 5.9 ± 1.3 0.08 ± 0.95 0.94
Fasting glucose, mg/dl 100.0 ± 27.0 3.00 ± 57.35 101.3 ± 24.8 1.39 ± 18.35 0.56
Creatinine, mg/dl 1.2 ± 0.8 −0.02 ± 0.82 1.3 ± 1.0 −0.05 ± 0.82 0.17
Potassium, mmol/l 4.1 ± 0.5 0.02 ± 0.47 4.1 ± 0.5 0.03 ± 0.50 0.70
eGFR, ml/min/1.73 m2 62.3 ± 18.7 −1.79 ± 12.61 64.0 ± 20.5 −0.24 ± 13.15 0.23














Petrella et al. compared the tolerability of ARBs to other
antihypertensive medications, and found that patients
treated with the former were less likely to experience a
cardiovascular event [26]. These data demonstrate the
favourable safety profile of both classes of drug.
Limitations
There were a number of limitations to the present regis-
try. Firstly, owing to the inherent characteristics of an
observational study, treatment allocation was not rando-
mised and thus patient characteristics and BP values at
Fig. 3 AZL-M vs. ACE-inhibitors in patients with a 12 month follow-up–any AE. Legend: HT, hypertension; BMI, body mass index
Fig. 4 AZL-M vs. ACE-inhibitors in patients with a 12 month follow-up–no treatment target adjustment. Legend: HT, hypertension; BMI, body
mass index
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baseline not comparable. This resulted in an imbalance
in patient number between the two groups, although the
sizes of both were high overall. Furthermore, ramipril
was the most commonly prescribed ACE-inhibitor, and
while a limited number of others were allowed, the num-
bers of patients were not high enough to draw compari-
sons between them. Another limitation is that the
medication regime was left to the discretion of the treat-
ing physician, which may have resulted in patients with
certain characteristics being preferentially prescribed
one class of drug over the other. This would likely intro-
duce a level of bias to the data. Finally, the incidence of
AEs was extremely low in both patient groups, making it
difficult to satisfactorily determine differences between
the two classes of drug. AEs further were tracked more
closely in the AZL-M arm, giving rise to the speculation
that rates in the ACEi arm are actually higher than
reported.
Conclusions
In conclusion, data from this study may help to inform
clinical decisions as to which is the most appropriate
RAS-targeted antihypertensive agent. The relative im-
pact of ACE-inhibitors versus ARBs on the rate of spe-
cific cardiovascular events and other clinically relevant
endpoints is yet to be resolved. However, this study adds
to the body of literature suggesting that when BP is
taken as the sole measure of the efficacy of these drugs,
AZL-M is more effective than ACE-inhibitors. Moreover,
this study indicates that data from clinical trials of AZL-
M may be extrapolated to real life clinical practice.
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